|
|
|
|
|
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting
|
|
|
|
|
|
Oral Abstract Session: Late-Breaking Abstract Session: Presentation and Discussion
|
|
| Phase 3 THOR Study: Results of Erdafitinib Versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
|
| Yohann Loriot, MD, Ph.D.
|
| Yohann Loriot discusses the results of the phase 3 THOR study assessing erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. Dr. Loriot notes that there is an unmet need for post-checkpoint inhibitor therapies in the metastatic urothelial carcinoma population.
|
|
|
|
|
|
| Discussant: THOR – Results of Erdafitinib versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
|
| Daniel Petrylak, MD
|
| In this presentation Daniel Petrylak discusses the results of the phase 3 THOR study. All metastatic urothelial patients should be tested for FGFR3/2 alterations, preferably at first diagnosis. The THOR study demonstrates superior overall survival, progression free survival, and objective response rates of erdafitinib compared to single agent chemotherapy in patients with FGFR3/2 alterations.
|
|
|
|
|
|
|
Oral Abstract Session: Genitourinary Cancer--Kidney and Bladder
|
|
| Efficacy and Safety of Atezolizumab + Cabozantinib vs Cabozantinib Alone After Progression with Prior Immune Checkpoint Inhibitor Treatment in Metastatic RCC: Primary PFS Analysis from the Phase 3, Randomized, Open-Label CONTACT-03 Study
|
| Toni K. Choueiri, MD
|
| Toni Choueiri discusses the primary progression free survival analysis from the phase 3, randomized, open-label CONTACT-03 study. CONTACT-03 was the first randomized, phase III trial to examine the efficacy and safety of a PD-L1 inhibitor following progression on or after prior treatment with PD-L1/PD-1 therapy.
|
|
|
|
|
|
| Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426
|
| Brian Rini, MD, FASCO
|
| Brian Rini discusses the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (RCC).
|
|
|
|
|
|
|
Poster Discussions: Genitourinary Cancer
|
|
| CABOSUN II: Results from a Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib vs. Sunitinib for Non-Clear Cell RCC |
| Andrew Johns, MD |
| Andrew Johns discusses the results of CABOSUN II, a phase 2, open-label, multi-center randomized study of cabozantinib vs. sunitinib for non-clear cell RCC. Cabozantinib was not superior to sunitinib for metastatic non-clear cell RCC in this study. Both arms had high rates of stable disease or better. Despite stratification by papillary RCC or non-papillary RCC, there were major differences in non-papillary RCC. |
|
|
|
|
|
| Hospital Anxiety and Depression Scale Score Trends Among Testicular Cancer Survivors: A Longitudinal Study
|
| Khalid Y. Alkhatib, MD, MMSc
|
| The rarity of testicular germ cell tumors, in conjunction with the young age of its patients, makes it challenging to study its long-term adverse effects. It is believed that the psychosocial state of testicular cancer patients is adversely impacted during treatment and survivorship. As such, Khalid Alkhatib and colleagues sought to investigate the changes in HADS scores over time in our institutional cohort of testicular cancer survivors, hypothesizing that anxiety and depression indices will improve over time, and specifically after treatment completion.
|
|
|
|
|
|
| Tumor Dosimetry of 177Lu-PSMA-617 for the Treatment of mCRPC: Results from the VISION Trial Sub-Study |
| Prof. Dr. med. Bernd Krause |
| Despite significant therapeutic advances in recent years, mCRPC remains an incurable and fatal disease. In the landmark VISION trial, 177Lu-PSMA-617 + protocol-permitted standard of care significantly improved overall survival and radiographic progression-free survival compared with standard of care alone, in patients with PSMA-positive mCRPC. |
|
|
|
|
|
| PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 + Standard of Care and Standard of Care Alone in Patients with mHSPC |
| Scott T. Tagawa, MD, MS, FACP |
| Scott Tagawa discusses PSMAddition, a phase 3 trial comparing 177Lu-PSMA-617 + standard of care and standard of care alone in patients with metastatic hormone-sensitive prostate cancer. ADT and androgen receptor pathway inhibitors may alter PSMA expression and radiosensitivity. As such, PSMAddition will assess the efficacy and safety of 177Lu-PSMA-617 plus standard of care versus standard of care alone in adults with mHSPC. |
|
|
|
|
|
| Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate, in Patients with Advanced Prostate Cancer |
| Neal D. Shore, MD, FACS |
| PRL-02 is a long-acting intramuscular depot injection of abiraterone decanoate, a novel prodrug of abiraterone delivered through the lymphatic system. PRL-02 potently blocks androgen production with minimal increases in mineralocorticoids or decreases in glucocorticoids through preferential inhibition of Cytochrome P450 (CYP)17 lyase versus CYP17 hydroxylase. |
|
|
|
|
|
|
|
|
|
|
| Phase I Dose-Escalation Results of PSMA Targeted Radionuclide Therapy with Alpha-Radiolabeled Antibody 225Ac-J591 and Beta-Radioligand 177Lu-PSMA I&T |
| Scott T. Tagawa, MD, MS, FACP |
| PSMA has already been utilized as a target to generate a therapeutic response – with the approval of Pluvicto (based on the VISION trial data), PSMA targeted therapy has become an important adjunctive treatment in patients with mCRPC. However, PSMA may be targeted by antibodies (mAb) or small molecules (SML), with different kinetics and biodistribution. |
|
|
|
|
|
| Final Results from Phase I Study of PSCA-Targeted CAR T Cells in Patients with mCRPC |
| Tanya Dorff, MD |
| In this presentation, Tanya Dorff discusses the final results from a phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). Based on this data, Dr. Dorff and colleagues report that PSCA-CAR T cells have anti-cancer activity in mCRPC with DLT of cystitis. PSCA is rest in mCRPC, with >80% screened patient having at least 2+ tissue expression. |
|
|
|
|
|
| Discussant: Looking Ahead: Novel Agents in Castration-Resistant Prostate Cancer
|
| Pedro C. Barata, MD, MSc
|
| Pedro Barata provides a discussion of novel therapeutic agents for castration resistant prostate cancer. He emphasizes that PSCA appears to be a good target for metastatic castration resistant prostate cancer. Lymphodepletion chemotherapy process allows expansion and persistence of CAR-T cells but it can contribute to dose limiting toxicities such as cystitis. Safety is still a concern for CAR-T technology. It is not enough to have a good target and likely success depends on multiple factors.
|
|
|
|
|
|
| Tumor Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study
|
| Fortis Gaba, MD
|
| Fortis Gaba discusses the results from the RESECT study assessing tumor factors and the variation in non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection surgery between sites. Quality transurethral resection (TURBT) for urothelial carcinoma is a vital component of appropriate staging of patients prior to embarking on treatment for either non-muscle or muscle invasive disease.
|
|
|
|
|
|
|
|
|
|
|
| Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial |
| Minas P. Economides, MD |
| Minas Economides discusses the results of a phase 2 trial assessing long-term outcomes of pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder. |
|
|
|
|
|
| FGFR3 Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients with Invasive Urothelial Carcinoma |
| Petros Grivas, MD, Ph.D.
|
| Petros Grivas discusses FGFR3 alterations in PROOF 302. PROOF 302 investigated the efficacy and safety of adjuvant infigratinib vs placebo in patients with high-risk invasive urothelial carcinoma. FGFR3 alterations were seen in only 19% of all patients screened for PROOF-302, a trial that was enriched for upper tract urothelial carcinoma: 30% of upper tract urothelial carcinoma and 13% of urothelial carcinoma of the bladder. |
|
|
|
|
|
| Discussant: Optimizing Outcomes in Upfront Management of Localized Bladder Cancer
|
| Maria De Santis, MD
|
| Maria De Santis discussed three abstracts including, Results from the RESECT study” presented by Fortis Gaba, “Long-term outcomes of pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder, presented by Minas Economides, and “FGFR3 alterations in PROOF 302, presented by Petros Grivas.
|
|
|
|
|
|
|
